**Hypoglycaemia, Cardiovascular Disease, and Mortality in Diabetes: Epidemiology, Pathogenesis, and Management**

*International Hypoglycaemia Study Group. (2019). Hypoglycaemia, cardiovascular disease, and mortality in diabetes: Epidemiology, pathogenesis, and management. The Lancet. Diabetes & Endocrinology, 7(5), 385.*

Hypoglycaemia is recognised as one of the most dangerous side-effects of treatment of diabetes with insulin or insulin secretagogues. Hypoglycemia has the potential to disrupt cerebral function and is associated with an increased risk of cardiovascular events and mortality.

This review explores the epidemiology of hypoglycaemia and cardiovascular disease, identifies potential mechanisms, explains the competing hypotheses, considers what additional research is required and suggests how the issue might be approached.

Collectively, these findings emphasise the importance of carefully balancing the potential benefits and potential harms, and individualising glycaemic goals in people with diabetes treated with insulin or an insulin secretagogue.